|Cancer||Cell death||Cell cycle||Cytoskeleton||Exo/endocytosis||Differentiation||Division||Organelles||Signalling||Stem cells||Trafficking|
Cell Biology International (2007) 31, 615619 (Printed in Great Britain)
Lycium barbarum polysaccharides regulate phenotypic and functional maturation of murine dendritic cells
Jie Zhua, Lu‑Hang Zhaoab*, Xiao‑Ping Zhaoc and Zhi Chenb
aDepartment of Biochemistry and Molecular Biology, College of Medicine, Zhejiang University, Hangzhou 310006, Republic of China
bExperimental Center for molecule and cell biology, College of Medicine, Zhejiang University, Hangzhou 310006, Republic of China
cZhejiang Medical College, Hangzhou 310053, Republic of China
Lycium barbarum polysaccharides (LBPs) have been known to have a variety of immunomodulatory functions including activation of T cells, B cells and NK cells. Dendritic cells (DC) are potent antigen-presenting cells that play pivotal roles in the initiation of the primary immune response. However, little is known about the immunomodulatory effects of LBPs on murine bone marrow derived dendritic cells (BMDC). In the present study, the effects of LBPs on the phenotypic and functional maturation of murine BMDC were investigated in vitro. Compared to the BMDC that were only subjected to treatment with RPMI1640, the co-expression of I-A/I-E, CD11c and secretion of IL-12 p40 by BMDC stimulated with LBPs (100
Keywords: Lycium barbarum polysaccharides (LBPs), Dendritic cells (DC), Mixed lymphocyte reaction (MLR).
*Corresponding author. Department of Biochemistry and Molecular Biology, College of Medicine, Zhejiang University, Hangzhou 310006, Republic of China. Tel./fax: +86 571 8721 7415.
Lycium barbarum, a well-known Chinese traditional medicine and also an edible food, plays multiple roles in pharmacological and biological functions including anti-aging activity, hypoglycemic and hypolipidemic effects, strengthening yang and improving eyesight. It has been reported that polysaccharides purified from Lycium barbarum are especially effective in modulating immune functions and inhibiting tumor growth (Gong et al., 2005; Gan et al., 2004; Cao et al., 1994). The immuno-modulation effects of LBPs are extensive, including increasing macrophage phagocytosis, the form of antibody secreted by spleen cells, spleen lymphocyte proliferation and CTL activity. Recently, the antitumor effects of LBPs have been investigated and are believed to be going through immune mechanisms (Gan et al., 2003, 2004).
DC, one of the most potent antigen-presenting cells (APC), are important for the initiation of primary immune response of both helper and cytotoxic T lymphocytes (Banchereua et al., 2000; Banchereua and Steinman, 1998; Lanzavecchia and Sallusto, 2001; Liu, 2001). After antigen capture, the DC precursors migrate to T cell regions of draining lymph nodes where they mature into functional DC. The functional DC further stimulate naive T cells by triggering the signaling pathway involving both major histocompatibility complex (MHC) molecules presenting antigen-peptides and co-stimulatory molecules (Austyn et al., 1988; Rock, 1996). The initial contact between DC and resting T cells may be mediated by a transient, high affinity interaction between DC-SIGN on the DC and the adhesion molecule ICAM-3 on the T cells (Geijtenbeek et al., 2000), followed by interactions through other adhesion molecules and their corresponding ligands (ICAM-1/LFA-1, LFA-1/CD2). Following TCR engagement, an intimate interaction often referred to as the immunological synapse evolves, where multiple interactions between co-stimulatory molecules on DC and their ligands on T cells result in final DC maturation and T cell activation (Banchereua et al., 2000; Lanzavecchia and Sallusto, 2000). There are no reports about LBPs inducing maturation of murine BMDC. Therefore, LBPs regulating phenotypic and functional maturation of murine BMDC were investigated in this study.
2 Materials and methods
2.1 Source of mice
Male or female C57BL/6J (H-2b) and BALB/c (H-2d) mice were purchased from the Department of Experimental Animal, College of Medicine, Zhejiang University, Hangzhou, China. Mice were used at 4–6
2.2 Source of drugs
LBPs were purchased from Pharmagenesis Beijing Office. The percentage of polysaccharide of LBPs was about 84.32% according to the phenol-sulfuric acid colorimetric method. The molecular weights of LBPs were estimated to be 31,000 through high performance gel filtration chromatography. The LBPs mainly consist of mannose, glucose, galactose, arabinose, rhamnose and xylose.
2.3 Generation of bone marrow-derived murine myeloid DC
DC were prepared as described previously with minor modifications (Inaba et al., 1992). Briefly, bone marrow cells were flushed from the femur and tibiae of C57BL/6J mice and depleted of RBC by hypotonic lysis using Tris-NH
2.4 Flow cytometric analysis
Cell surface expression of I-A/I-E or CD11c was determined by immunofluorescence staining. On day 7, cells were harvested, washed twice with PBS, and resuspended in washing buffer (PBS containing 2% FCS and 0.1% sodium azide). Cells were first blocked with 20% mixed mouse and rat serum for 15
2.5 Cytokine assay
On day 7, DC culture supernatants were collected and the concentration of mouse IL-12 p40 unit was determined by a sandwich enzyme-linked immunosorbent assay (ELISA) kit (Biosource) according to the manufacturer's instructions. Cytokine concentrations were determined according to absorbance readings at 450
2.6 Endocytos is assay
In order to analyze the endocytic capacity of DC on day 7, 1
2.7 Mixed lymphocyte reaction (MLR) induced by DC
Responder mononuclear lymphocytes from H-2d BALB/c's splenocytes were isolated by Ficoll-Urografin density gradient. On day 7, mature DC were harvested as inducers, treated with 25
The results were expressed as means
3.1 LBPs up-regulate the co-expression of I-A/I-E and CD11c on DC surface
Flow cytometric analysis of DC treated with RPMI 1640, LBPs or LPS. On day 5 of DC culture, cells were incubated at a concentration of 1
3.2 LBPs increase IL-12 p40 production of DC
Production of IL-12 p40 in culture supernatants of DC treated with RPMI 1640, LBPs or LPS. On day 5 of DC culture, cells were incubated at a concentration 1
3.3 LBPs inhibit the FITC-dextran uptake by DC
Mannose-receptor-mediated endocytosis was analyzed by the uptake of FITC-dextran. In DC treated by LBPs (100
Antigen uptake by DC stimulated by RPMI 1640, LBPs or LPS. On day 5 of DC culture, cells were incubated at a concentration of 1
3.4 LBPs facilitate the allostimulatory capacity of DC
The effects of LBPs on MLR induced by DC are illustrated in Fig. 4. LBPs (100
Lymphocyte proliferation of MLR induced by DC. On day 5 of DC culture, cells were incubated with 100
It has been well-known for decades that LBPs are biologically active components of Lycium barbarum with potential pharmacological and biological functions. This is the first report that we are aware of showing the effects of LBPs on the generation and maturation of murine BMDC. In this study, we have shown that LBPs can induce maturation of murine BMDC and ready them for T cell-mediated immune responses. LBPs significantly increase the expression of membrane molecules I-A/I-E and CD11c. Meanwhile, LBPs markedly reduce the endocytic activity of DC and augment their capacity to promote the proliferation of naïve allogeneic T cells.
DC can differentiate from immature to mature stages by various stimulators, by cytokines such as TNF-α or pathogen products, or LPS (Banchereua et al., 2000). Immature DC have a high capacity for antigen capture and processing. Maturation of DC are characterized by a decreased antigen processing capacity, an increased cell surface expression of MHC and co-stimulatory molecules, and the secretion of IL-12, priming strong stimulation of CD4+ and CD8+T lymphocyte growth and differentiation (Banchereua et al., 2000; Banchereau and Steinman, 1998; Lanzavecchia and Sallusto, 2001). Mature DC can secrete IL-12 p70, the active protein, and then prime Th1 lymphocyte transformation. IL-12 p40 is a subunit of IL-12 p70, whose expression is inducible and correlated with the production of bioactive IL-12 p70 by DC; while another subunit, IL-12 p35, is encoded on separate genes and constitutively expressed by a variety of cell types (Schoenhaut et al., 1992; Trinchieri, 1995). Our data indicate that exposure to LBPs increase the production of bioactive IL-12 p70 in murine BMDC in the presence of GM-CSF/IL-4. Also, we investigated the capacity of LBPs-treated DC to internalize FITC-dextran via mannose receptor-mediated endocytosis. Both mechanisms are complex, energy-dependant processes that require the coordinated action of the actin cytoskeleton and are characteristic and distinctive properties of immature vs. mature DC (Sallusto et al., 1995; Garrett and Mellmann, 1999). These data further support the view that exposure to LBPs promotes the generation of functionally active, mature DC.
It is well-known that tumors are sources of biological substances and release certain immunosuppressive factors to evade the immune surveillance system of the host (Kanto et al., 2001). Through analysis of tumor specimens obtained from patients, a reduced number of DC infiltrated into tumors correlated with a poor prognosis for patients (Zeid and Muller, 1993; Tsuge et al., 2000). Also, the phenotypes and function of DC could be altered in tumors. The reduction of expression of co-stimulatory molecules, defective cytokine production, and full allostimulatory activity could be found in DC infiltrated into tumor tissue, which implies that tumor-derived factors can impede DC maturation (Gabrilovich et al., 1997; Troy et al., 1998). These effects appear to be maturation-dependent, acting only on DC precursors and not mature DC. Therefore, it may be better to use mature DC for clinical applications.
LBPs as a traditional Chinese herb have been extensively used in improving the immune activity of patients treated by chemical or radiation therapy. According to the results of this study, LBPs enhance the phenotypic and functional maturation of DC. Therefore, LBPs may increase the antitumor effects of DC-based vaccine therapy. Now we are investigating the antitumor effects of a combination therapy through an LBPs- and DC-based vaccine in a tumor-bearing mouse model.
We sincerely thank Mr. Janping Pan for his excellent technical and theoretical assistance.
Austyn JM, Kupiec-Weglinski, JW, Hankins, DF, Morris, PJ. Migration patterns of dendritic cells in the mouse. Homing to T cell-dependent areas of spleen, and bingding within marginal zone. J Exp Med 1988:167:646-51
Cao GW, Yang, WG, Du, P. Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients. Zhonghua Zhong Liu Za Zhi 1994:16:428-31
Gan L, Zhang, SH, Liu, Q, Xu, HB. A polysaccharide-protein complex from Lycium barbarum upregulates cytokine expression in human peripheral blood mononuclear cells. Eur J Pharmacol 2003:3:217-22
Garrett WS, Mellmann, I. Studies of endocytosis. Dendritic Cells 1999:693
Geijtenbeek TH, Torensma, R, van Vliet, SJ, van Duijnhoven, GC, Adema, GJ, van Kooyk, Y. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000:100:575-85
Gong H, Shen, P, Jin, L, Xing, C, Tang, F. Therapeutic effects of Lycium barbarum polysaccharide (LBP) on irradiation or chemotherapy-induced myelosuppressive mice. Cancer Biother Radiopharm 2005:20:155-62
Inaba K, Inaba, M, Romani, N, Aya, H, Deguchi, M, Ikehara, S. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992:176:1693-702
Sallusto F, Cella, M, Danieli, C, Lanzavecchia, A. Dendritic cells used macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995:182:389-400
Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995:13:251-76
Received 9 March 2006/19 November 2006; accepted 15 December 2006doi:10.1016/j.cellbi.2006.12.002